Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01085656 · ClinicalTrials.gov registry record · Phase 1
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
A Phase 1 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01085656 is a Phase 1 study that was terminated before completion, run by University of Florida. The registered enrollment target is 18 participants.
The verdict
NCT01085656, a Phase 1 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.
Interventions
- DRUG OXi4503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-02 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01085656
The ClinicalTrials.gov registry entry for NCT01085656 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OXi4503 is the first listed.
NCT01085656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01085656 about?
NCT01085656 is a clinical study titled "A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS". This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.
What is the current status of trial NCT01085656?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-02. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01085656?
The interventions under investigation include: OXi4503 (DRUG).
Who is sponsoring clinical trial NCT01085656?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.